AC
PCRX icon

Ascend Capital’s Pacira BioSciences PCRX Stock Holding History

Ascend Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-258,557
Closed -$8.35M – 170
2016
Q4 		$8.35M Buy
+258,557
New +$8.63M 0.42% 75
2015
Q2 		– Sell
-40,000
Closed -$3.55M – 182
2015
Q1 		$3.55M Buy
+40,000
New +$4.06M 0.12% 126

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's PCRX Position: Q1 2017 in Review

Ascend Capital sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 258,557 shares — an estimated $8.35M sold.

Ascend Capital first reported a position in PCRX in Q1 2015 and held it in 2 quarters. The position peaked at $8.35M in Q4 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

  • Ascend Capital reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
  • Ascend Capital sold 258,557 Pacira BioSciences shares in Q1 2017, an estimated $8.35M.
  • Ascend Capital first reported a position in Pacira BioSciences in Q1 2015 and held it in 2 quarters.
  • Ascend Capital's Pacira BioSciences position peaked at $8.35M in Q4 2016.
  • 192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Ascend Capital's 13F filing for Q1 2017, filed 15 May 2017.